Abstract |
The immunocytochemical expression of the antigen reacting with the monoclonal antibody Ki-67 (Ki-67 positivity) was investigated in 50 imprint preparations from human brain tumours. Data were related to tumour proliferative activity, as determined from in vivo bromodeoxyuridine ( BrdU) incorporation ( BrdU-labelling index, BrdU-LI) and histology. The percentage of Ki-67-positive cells was greater than the corresponding BrdU-LI value in all tumours, and the differences in Ki-67 positivity among tumour subtypes paralleled the BrdU-LI differences. Both the BrdU-LI and the percentage of Ki-67 positive cells were significantly greater (P less than 0.005) in the group of clinically aggressive adult tumours, histologically identified as anaplastic astrocytomas and glioblastomas, than in the less aggressive ones ( oligodendroglioma, meningiomas, schwannomas, pituitary adenomas, dermoid cyst) and in the cerebral metastatic localizations. These data suggest that Ki-67 positivity, which is easily evaluated with immunocytochemistry, is related to the proliferative activity of brain tumours and that this parameter is endowed with clinical significance.
|
Authors | M Girino, A Riccardi, M Danova, P Gaetani, G Butti, M Giordano, A Cuomo |
Journal | Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology
(Anal Cell Pathol)
Vol. 2
Issue 5
Pg. 269-75
(Sep 1990)
ISSN: 0921-8912 [Print] Netherlands |
PMID | 2275874
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, Surface
- Ki-67 Antigen
- Nuclear Proteins
- Bromodeoxyuridine
|
Topics |
- Antibodies, Monoclonal
- Antigens, Surface
(analysis)
- Brain Neoplasms
(chemistry, pathology)
- Bromodeoxyuridine
(metabolism)
- Cell Division
(physiology)
- Humans
- Immunohistochemistry
- Ki-67 Antigen
- Nuclear Proteins
(analysis)
|